Hematology

April 27, 2021

Avapritinib shows important efficacy in the treatment of advanced systemic mastocytosis

The potent KITD816V inhibitor induced durable responses that deepened over time in patients with this disease, regardless of prior therapy or the presented subtype  A provisional and pre-specified analysis of PATHFINDER (NCT03580655), a phase II, open-label and […]
April 23, 2021

EVICTION is the first-in-human trial of γ9δ2 T-cell antitumor response in solid and hematological tumors with the ICT01 drug

Gamma9 Delta2 (γ9δ2) T cells function at the crossroads of innate and adaptive immunity, with important roles in immune responses against pathogens and carcinogenesis, making them an attractive […]
April 22, 2021

Combination copanlisib plus rituximab demonstrates broad efficacy and superiority versus placebo plus rituximab in patients with relapsed iLNH

Rituximab-based therapies are standard in the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (iLNH). Copanlisib, an intravenous PI3K inhibitor, has demonstrated efficacy and safety as monotherapy […]
July 17, 2020

Conditioning regimens for allogeneic stem cell transplantation in children and adolescents with acute lymphocytic leukemia

Overall survival and event-free survival were higher in the group with total body irradiation and treatment-related mortality was higher in the group with chemotherapy At the […]
April 20, 2020

FDA approves luspatercept-aamt for anemia in adults with myelodysplastic syndromes

Efficacy was demonstrated in a study involving 153 patients The U.S. Food and Drug Administration (FDA) has approved luspatercept-aamt (REBLOZYL®) for the treatment of anemia in […]
April 16, 2020

COVID-19 management strategy in pediatric hematology and oncology departments

Last week, The Lancet Haematology magazine published a strategic plan, developed by a Chinese group, for the management of outbreaks of COVID-19 in pediatric hematology and […]
January 10, 2019

FDA Approves Tagraxofusp for Rare Hematologic Cancer

Tagraxofusp-erzs™ (Elzonris) infusion was granted US Food and Drug Administration (FDA) approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to news releases […]